Search clinical trials for: Atezolizumab and Talazoparib

Total 272495 results

Samsung Medical Center

Not yet recruiting

PALbociclib Endocrine Therapy Followed by Talazo vs. Talazoz-Atezo Study (Young-PALETTA)

Premenopausal HR+/HER2- Metastatic Breast Cancer

Korea, Republic of
National Cancer Institute (NCI)

Terminated

BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment

Ovarian Cancer

United States
Seoul National University Hospital

Recruiting

Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

Advanced Breast Cancer

Korea, Republic of
Mylin A. Torres, MD
Pfizer; Genentech, Inc.; Emory University

Terminated

A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer (TARA)

Breast Cancer | Triple Negative Breast Cancer

United States
Center Trials & Treatment
BioGene Pharmaceutical

Withdrawn

Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors

Breast Neoplasm | Advanced or Recurrent Solid Tumors

Albania
Pfizer

Completed

STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS

Neoplasms

China
Pfizer

Active, not recruiting

A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

Neoplasms | Breast Neoplasms

Japan
Pfizer

Terminated

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Early Breast Cancer

United States
Melinda Telli
Pfizer; BioMarin Pharmaceutical

Completed

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

Advanced Breast Cancer | HER2/Neu Negative | Triple-Negative Breast Cancer

United States
Pfizer
Medivation, Inc.; Myriad Genetic Laboratories, Inc.

Terminated

A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study) (ABRAZO)

Breast Neoplasms | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

United States, Spain, United Kingdom, Germany, France
Brown University
Pfizer; Lifespan

Terminated

BrUOG 390: Neoadjuvant Treatment With Talazoparib

Ovarian Cancer | Fallopian Tube Cancer | BRCA1 Mutation | BRCA2 Mutation | High Grade Serous Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (POSITION)

Fallopian Tube Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Stage III Fallopian Tube Cancer AJCC v7 | Stage III Ovarian Cancer AJCC v6 and v7 | Stage III Primary Peritoneal Cancer AJCC v7 | Stage IIIA Fallopian Tube Cancer AJCC v7 | Stage IIIA Ovarian Cancer AJCC v6 and v7 | Stage IIIA Primary Peritoneal Cancer AJCC v7 and other conditions

United States
Pfizer
Medivation, Inc.

Completed

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (EMBRACA)

Breast Neoplasms | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

Korea, Republic of, United States, Australia, Spain, Belgium, France, Ireland, Taiwan, Poland, Germany, Israel, Brazil, United Kingdom, Italy, Russian Federation, Ukraine
Stanford University
Pfizer

Recruiting

Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

Breast Cancer | Advanced Breast Cancer

United States
First Affiliated Hospital of Zhejiang University
Hoffmann-La Roche; Geneplus-Beijing Co. Ltd.

Unknown

The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients

Non-Small Cell Lung Cancer

China
Centre Francois Baclesse
Pfizer

Recruiting

TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma (TALASUR)

Urothelial Carcinoma

France
Pfizer
Astellas Pharma Inc

Active, not recruiting

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC (TALAPRO-2)

mCRPC

China, Finland, Spain, United States, Hungary, Israel, Belgium, Korea, Republic of, France, Canada, Czechia, Australia, Japan, Brazil, Germany, Argentina, New Zealand, United Kingdom, Norway, South Africa, Poland, Portugal, Chile, Italy, Pe... and more
University Health Network, Toronto
Pfizer

Recruiting

Talazoparib and Thoracic RT for ES-SCLC

Lung Cancer | Small-Cell Lung Cancer

Canada
Erasmus Medical Center
University Medical Center Groningen; Leiden University Medical Center

Recruiting

FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test (FUTURE)

Advanced Breast Cancer

Netherlands
Seoul National University Hospital

Unknown

The Efficacy of Neoadjuvant Atezolizumab Treatment in Patients With Advanced Urothelial Bladder Cancer

Urothelial Carcinoma
University of Southern California
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditions

United States
Intergroupe Francophone de Cancerologie Thoracique
Roche Pharma AG; GFPC

Completed

Atezolizumab Combined With Chemotherapy in Extensive Stage SCLC (CLINATEZO)

Small Cell Lung Cancer

France
Pfizer

Completed

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | NSCLC | Prostate Cancer | Advanced Solid Tumors | Solid Tumors

United States, Australia
Yonsei University

Not yet recruiting

Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer (SKYROCKET)

Non-small Cell Lung Cancer

Korea, Republic of
University Medical Center Groningen
Hoffmann-La Roche; Amsterdam UMC, location VUmc; Stichting Hemato-Oncologie voor...

Withdrawn

Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Netherlands
University Medical Center Groningen

Terminated

89Zr-atezolizumab PET Scan and Lobular Breast Cancer (ImaGelato)

Lobular Metastatic Breast Cancer

Netherlands
Immune Design
Genentech, Inc.

Terminated

Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)

Sarcoma | Myxoid/Round Cell Liposarcoma | Liposarcoma | Synovial Sarcoma | Recurrent Adult Soft Tissue Sarcoma | Metastatic Sarcoma | Locally Advanced Sarcoma

United States
Pfizer
Astellas Pharma Inc

Active, not recruiting

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Prostate Cancer

United States, Finland, China, France, Spain, Hungary, United Kingdom, Korea, Republic of, Canada, Czechia, Taiwan, Belgium, Australia, Argentina, Japan, Germany, India, Turkey, Slovakia, Russian Federation, Bulgaria, Italy, Ukraine, ... and more
University of Maryland, Baltimore
Pfizer; Van Andel Research Institute

Completed

Decitabine and Talazoparib in Untreated AML and R/R AML (1565GCC)

Acute Myeloid Leukemia

United States
Corvus Pharmaceuticals, Inc.
Genentech, Inc.

Completed

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

Renal Cell Cancer | Metastatic Castration Resistant Prostate Cancer

United States, Canada, Australia
Incyte Corporation
Hoffmann-La Roche; Genentech, Inc.

Terminated

A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)

UC (Urothelial Cancer) | NSCLC (Non-small Cell Lung Carcinoma)

United States
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Terminated

Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma

Lymphoma

United States
Hoffmann-La Roche

Completed

A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Neoplasms

Belgium, France, Spain
Chonnam National University Hospital
Roche Pharma AG

Completed

Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY] (BUDDY)

Lung Neoplasm Malignant

Korea, Republic of
M.D. Anderson Cancer Center

Not yet recruiting

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

Prostate Cancer

United States
Astellas Pharma Global Development, Inc.

Completed

A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

United States
The Netherlands Cancer Institute
Roche Pharma AG

Completed

Carboplatin-cyclophosphamide Combined With Atezolizumab (PROLOG)

Breast Cancer | Ovarian Cancer | Cervix Cancer | Endometrial Cancer

Netherlands
Yale University

Terminated

Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma

Asymptomatic Myeloma

United States
Celldex Therapeutics
Genentech, Inc.

Terminated

A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer

Melanoma | Neoplasms | Neoplasms by Histologic Type | Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Urogenital Neoplasms | Kidney Diseases | Urologic Diseases | Head and Neck Cancer | Bladder Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Clear-cell Metastatic Renal Cell Carcinoma

United States
Pfizer

Terminated

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors

United States, Canada, United Kingdom, Korea, Republic of, Australia, Belgium, Denmark, Hungary, Russian Federation
German Cancer Research Center

Not yet recruiting

Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia (NAKIP-AML)

Acute Myeloid Leukemia
Hunan Province Tumor Hospital

Completed

Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Completed

Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer

China
Clovis Oncology, Inc.
Genentech, Inc.

Terminated

A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC

Non-small Cell Lung Cancer

United States
American Society of Clinical Oncology
Bristol-Myers Squibb; Eli Lilly and Company; Bayer; Merck Sharp & Dohme LLC; Pfizer; AstraZene... and other collaborators

Recruiting

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)

Lymphoma, Non-Hodgkin | Multiple Myeloma | Advanced Solid Tumors

United States
National Taiwan University Hospital
Roche Pharma AG; Ipsen

Recruiting

Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Cancer | Metastatic Cancer | Squamous Cell Carcinoma

Taiwan
Spanish Oncology Genito-Urinary Group
Roche Farma, S.A; Dynamic Science S.L.

Active, not recruiting

Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer

Bladder Cancer

Spain
Gruppo Oncologico Italiano di Ricerca Clinica

Recruiting

Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso) (AtezoMeso)

Mesotheliomas Pleural

Italy
Pfizer

Terminated

Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)

Ovarian Cancer

Korea, Republic of, United States, Singapore, Taiwan, Japan, Italy, Australia, Belgium, Ireland, Russian Federation
Melbourne Health
Sanofi; National Heart Foundation, Australia

Terminated

The Effect of Enoxaparin Sodium on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.

Deep Vein Thrombosis

Australia

Search clinical trials for: Atezolizumab and Talazoparib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations